The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC
Seung Yeon Oh(Yonsei University), Mi Ran Yun(Yonsei University)
Cited by 5
Related Papers
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
|Clinical Cancer Research|2020|115
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
|EMBO Molecular Medicine|2019|60